Foresee Pharmaceuticals Co., Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Taipei Taiwan (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2014
NCT02234115
First Marketed Drug
2021
leuprolide (lupron)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Foresee Pharma | Foresee Pharmaceuticals Co., Ltd. | FORESEE PHARMS

Active Ingredients

Marketed Drugs (1)

leuprolide (lupron) (2021)

Drugs in Phase 3 Trials (2)

fp-025 (4 trials)

leuprolide (lupron) (4 trials)

Drugs in Phase 2 Trials (1)

fp-045 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 2)

Asthma (Phase 2)

Carcinoma (Phase 3)

Fanconi Anemia (Phase 2)

Fanconi Syndrome (Phase 2)

Inflammation (Phase 2)

Prostatic Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 3